Oral hypoglycaemic agent

Reading File

Finding Sources

Searching PubMed

"oral hypoglycemic agents" AND "type 2 diabetes"

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

Reading File

I now have excellent, comprehensive content from both Katzung's Pharmacology and Lippincott's Pharmacology. I have enough to deliver a thorough, well-organized answer covering all major classes of oral hypoglycaemic agents.

Oral Hypoglycaemic Agents

Oral hypoglycaemic agents (OHAs) are drugs taken by mouth to lower blood glucose in type 2 diabetes mellitus. They are categorized based on their primary mechanism: insulin secretagogues, insulin sensitizers, glucose absorption inhibitors, glucose excretion enhancers, and incretin-based agents.

1. Sulfonylureas (Insulin Secretagogues)

Mechanism: Bind to a 140-kDa sulfonylurea receptor associated with an ATP-sensitive K⁺ channel (K-ATP channel) on pancreatic beta cells. Channel blockade causes membrane depolarization → voltage-gated Ca²⁺ channel opens → Ca²⁺ influx → insulin exocytosis. They are effective only if functioning beta cells remain (ineffective in Type 1 DM or after pancreatectomy).

First Generation

Drug	Half-life	Duration	Key Feature
Tolbutamide	4-5 h	6-10 h	Safe in elderly/renal impairment; max 3000 mg/day
Tolazamide	-	Intermediate	Less potent
Chlorpropamide	~36 h	Up to 60 h	Causes SIADH; avoid in elderly

Second Generation (higher receptor affinity, lower doses)

Drug	Dose	Key Feature
Glipizide	2.5-40 mg/day	Short-acting; renal-safe
Glyburide (glibenclamide)	1.25-20 mg/day	Active metabolites; risk in renal failure
Glimepiride	1-8 mg/day	Once daily; fewest interactions

Adverse effects: Hypoglycaemia (main risk), weight gain, skin rashes, rarely haematologic toxicity (leukopenia, thrombocytopenia <0.1%). Metabolized by the liver; metabolites excreted renally (or partly in bile for 2nd generation).

The UKPDS (UK Prospective Diabetes Study) found no excess cardiovascular mortality with sulfonylureas.

Katzung's Basic and Clinical Pharmacology, 16th Ed.

2. Biguanides (Insulin Sensitizer - Hepatic)

Drug: Metformin (only biguanide in current clinical use)

Mechanism: Activates hepatic AMP-activated protein kinase (AMPK), which:

Reduces hepatic gluconeogenesis and glycogenolysis
Reduces hepatic lipogenesis
Does NOT stimulate insulin release - no hyperinsulinaemia, no hypoglycaemia as monotherapy

Pharmacokinetics:

Half-life: 1.5-3 hours; not protein bound; excreted unchanged in urine
Not metabolized hepatically
eGFR ≥60: safe; eGFR 30-45: use cautiously; eGFR <30: contraindicated

Dosing: Start 500 mg daily with food, titrate to 1000 mg twice daily; max benefit at 2000 mg/day.

Adverse effects:

GI (nausea, diarrhoea, abdominal discomfort) in ~20% - dose-related, often transient; extended-release formulation reduces this
Lactic acidosis (rare) - risk increased in renal/hepatic failure, tissue hypoxia
Vitamin B12 malabsorption (long-term use) - due to impaired calcium-dependent ileal absorption of B12-intrinsic factor complex; monitor periodically

Benefits beyond glucose lowering:

UKPDS: metformin reduced cardiovascular and microvascular events in obese Type 2 diabetics
Diabetes Prevention Program: metformin prevents new-onset Type 2 DM in obese patients with impaired glucose tolerance
Possible reduction in cancer risk (epidemiological data)
Katzung's Basic and Clinical Pharmacology, 16th Ed.

3. Meglitinides (Short-Acting Insulin Secretagogues)

Drugs: Repaglinide, Nateglinide

Mechanism: Similar to sulfonylureas - close K-ATP channels on beta cells → depolarization → insulin release. However, they have a rapid onset and shorter duration making them "postprandial glucose regulators." Taken before each meal.

Metabolism:

Nateglinide: CYP2C9 and CYP3A4; metabolites excreted in urine
Repaglinide: CYP2C8 and CYP3A4; excreted in feces - safer in renal disease

Adverse effects: Hypoglycaemia and weight gain (less than sulfonylureas). Gemfibrozil markedly increases repaglinide levels (CYP2C8 inhibition) - concurrent use contraindicated. Do NOT combine with sulfonylureas (overlapping mechanism + severe hypoglycaemia risk).

Lippincott Illustrated Reviews: Pharmacology

4. Thiazolidinediones / TZDs (Insulin Sensitizers - Peripheral)

Drugs: Pioglitazone, Rosiglitazone

Mechanism: Agonists at PPARγ (peroxisome proliferator-activated receptor gamma), a nuclear hormone receptor. PPARγ activation upregulates transcription of insulin-responsive genes → increased insulin sensitivity in adipose tissue, liver, and skeletal muscle. Require insulin to act but do NOT promote its release.

Pharmacokinetics: Well absorbed orally, extensively bound to serum albumin, metabolized by CYP2C8. Pioglitazone: mainly biliary/fecal excretion. Rosiglitazone: mainly renal. No dose adjustment needed for renal impairment.

Adverse effects:

Weight gain (increased subcutaneous fat) and fluid retention
Heart failure exacerbation - avoid in symptomatic heart failure
Osteopenia and increased fracture risk in women
Pioglitazone: possible increased bladder cancer risk
Rosiglitazone: boxed warning - possible increased risk of MI and angina
Hepatotoxicity (rare) - monitor LFTs
Lippincott Illustrated Reviews: Pharmacology

5. DPP-4 Inhibitors ("Gliptins") - Incretin Enhancers

Drugs: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin, Vildagliptin

Mechanism: Inhibit DPP-4 (dipeptidyl peptidase-4), the enzyme that rapidly degrades incretin hormones (GLP-1 and GIP). This prolongs incretin activity, increasing glucose-dependent insulin secretion and suppressing glucagon - only when glucose is elevated (glucose-dependent effect, so low hypoglycaemia risk as monotherapy).

Figure: DPP-4 inhibitors block DPP-4, preventing inactivation of active GLP-1 and GIP secreted in response to a meal. (Lippincott Illustrated Reviews: Pharmacology)

Key pharmacokinetic notes:

All except linagliptin require dose reduction in renal impairment
Linagliptin: primarily eliminated via enterohepatic system - no renal dose adjustment needed
Saxagliptin: active metabolite; metabolized by CYP3A4/5

Adverse effects:

Generally well tolerated; nasopharyngitis and headache most common
Rare: serious hypersensitivity (anaphylaxis, angioedema, Stevens-Johnson syndrome), pancreatitis
Severe disabling joint pain (rare - FDA warning)
Saxagliptin and alogliptin: increased risk of heart failure hospitalization - use with caution

HbA1c reduction: ~0.5-1.0%

Katzung's Basic and Clinical Pharmacology, 16th Ed.; Lippincott Illustrated Reviews: Pharmacology

6. GLP-1 Receptor Agonists (Incretin Mimetics)

Drugs: Semaglutide (oral and injectable), Liraglutide, Dulaglutide, Exenatide, Lixisenatide

Mechanism: Mimic endogenous GLP-1 (glucagon-like peptide-1):

Glucose-dependent insulin secretion
Suppress postprandial glucagon
Slow gastric emptying → reduced postprandial hyperglycaemia
Central satiety enhancement → weight loss
Promote beta-cell proliferation

Incretin hormones account for 60-70% of postprandial insulin secretion. This "incretin effect" is markedly reduced in Type 2 diabetes.

Administration: Most are subcutaneous injections (not oral - polypeptides). Exception: oral semaglutide (Rybelsus) is the only oral GLP-1 agonist.

Cardiovascular benefits: Dulaglutide, liraglutide, and semaglutide are approved to reduce cardiovascular mortality, MI, and stroke in Type 2 DM with established cardiovascular disease.

Adverse effects: Nausea, vomiting, diarrhoea (common, especially on initiation), pancreatitis (rare), injection site reactions.

Lippincott Illustrated Reviews: Pharmacology

7. SGLT2 Inhibitors ("Gliflozins") - Glucose Excretion Enhancers

Drugs: Empagliflozin, Dapagliflozin, Canagliflozin, Ertugliflozin

Mechanism: Inhibit sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule, which normally reabsorbs ~90% of filtered glucose. Inhibition causes glucosuria (glucose excretion in urine) → blood glucose lowering, independent of insulin.

Additional benefits:

Osmotic diuresis and natriuresis → blood pressure reduction
Weight loss
Reduced cardiovascular mortality (empagliflozin, canagliflozin)
Reduce heart failure hospitalization (empagliflozin, dapagliflozin - also approved for HFrEF regardless of DM status)
Slow progression of diabetic kidney disease

Adverse effects:

Genital mycotic infections (glucosuria promotes fungal growth) - most common
Urinary tract infections
Euglycaemic DKA (rare but serious)
Canagliflozin: increased risk of lower limb amputation (FDA warning), bone fractures
Volume depletion/hypotension (especially with diuretics)
Katzung's Basic and Clinical Pharmacology, 16th Ed.; Lippincott Illustrated Reviews: Pharmacology

8. Alpha-Glucosidase Inhibitors

Drugs: Acarbose, Miglitol

Mechanism: Competitively inhibit intestinal alpha-glucosidases (enzymes that break down complex carbohydrates in the brush border), delaying glucose absorption from the gut → reduces postprandial hyperglycaemia.

Adverse effects: Flatulence, bloating, diarrhoea (due to unabsorbed carbohydrates fermenting in the colon). Must be taken with the first bite of a meal.

Summary Comparison Table

Class	Example(s)	Mechanism	Hypoglycaemia Risk	Weight Effect	Key Concern
Sulfonylureas	Glipizide, Glimepiride	K-ATP channel closure → insulin release	High	Gain	Hypoglycaemia
Biguanides	Metformin	↓ Hepatic gluconeogenesis (AMPK)	None	Neutral/loss	Lactic acidosis (rare); B12 deficiency
Meglitinides	Repaglinide	K-ATP closure (short-acting)	Moderate	Gain	Hypoglycaemia (less than SU)
TZDs	Pioglitazone	PPARγ agonist → insulin sensitivity	None	Gain	Heart failure, fractures
DPP-4 inhibitors	Sitagliptin, Linagliptin	Prolong GLP-1/GIP activity	Low	Neutral	Pancreatitis, joint pain
GLP-1 agonists	Semaglutide, Liraglutide	GLP-1 receptor activation	Low	Loss	Nausea/vomiting; pancreatitis (rare)
SGLT2 inhibitors	Empagliflozin, Dapagliflozin	Urinary glucose excretion	None	Loss	Genital infections, DKA (rare)
Alpha-glucosidase inhibitors	Acarbose	↓ Carbohydrate absorption	None	Neutral	GI flatulence

Clinical Notes

Metformin remains the first-line agent for Type 2 DM (unless contraindicated) per most guidelines.
In patients with established cardiovascular disease or heart failure, SGLT2 inhibitors or GLP-1 agonists with proven CV benefit are preferred add-on agents.
DPP-4 inhibitors + GLP-1 agonists should not be combined (overlapping mechanism, increased toxicity risk).
Meglitinides + sulfonylureas should not be combined (overlapping mechanism, severe hypoglycaemia).
Metformin is also used for prevention of Type 2 DM in high-risk individuals (impaired glucose tolerance, obesity).

Sources: Katzung's Basic and Clinical Pharmacology, 16th Ed.; Lippincott Illustrated Reviews: Pharmacology; Ganong's Review of Medical Physiology, 26th Ed.

This is a shared conversation. Sign in to Orris to start your own chat.